Go Pro
→ The 1934 playbook (From American Alternative) (Ad)tc pixel Free MIRA Stock Alerts

MIRA Pharmaceuticals (MIRA) Financials

MIRA Pharmaceuticals logo
$0.97 +0.04 (+3.99%)
As of 10:51 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for MIRA Pharmaceuticals

Annual Income Statements for MIRA Pharmaceuticals

This table shows MIRA Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -7.06 -12 -7.85 -32
Consolidated Net Income / (Loss)		 -7.06 -12 -7.85 -10
Net Income / (Loss) Continuing Operations		 -7.06 -12 -7.85 -10
Total Pre-Tax Income 		-7.06 -12 -7.85 -10
Total Operating Income		 -7.05 -8.53 -8.02 -10
Total Gross Profit		 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00
Operating Revenue		 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00
Total Operating Expenses		 7.05 8.53 8.02 10
Selling, General & Admin Expense		 2.99 6.50 4.71 8.77
Research & Development Expense		 2.35 1.57 3.31 1.72
Total Other Income / (Expense), net		 -0.01 -3.46 0.17 0.05
Interest Expense		 0.01 3.46 -0.17 -0.10
Other Income / (Expense), net		 - - 0.00 -0.05
Other Gains / (Losses), net		 - - - 0.05
Preferred Stock Dividends Declared		 - - 0.00 22
Basic Earnings per Share		 ($0.40) ($0.85) ($0.51) ($1.35)
Weighted Average Basic Shares Outstanding		 17.57M 13.92M 15.44M 23.69M
Diluted Earnings per Share		 ($0.40) ($0.85) ($0.51) ($1.35)
Weighted Average Diluted Shares Outstanding		 17.57M 13.92M 16.81M 42.02M
Weighted Average Basic & Diluted Shares Outstanding		 - 14.78M 16.81M 42.02M

Quarterly Income Statements for MIRA Pharmaceuticals

This table shows MIRA Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.59 -5.79 -1.72 -1.69 -2.04 -2.40 -1.78 -1.54 -23 -5.98 -1.15
Consolidated Net Income / (Loss)		 -3.59 -5.79 -1.72 -1.69 -2.04 -2.40 -1.78 -1.54 -1.14 -5.98 -1.15
Net Income / (Loss) Continuing Operations		 -3.59 -5.79 -1.72 -1.69 -2.04 -2.40 -1.78 -1.54 -1.14 -5.93 -1.15
Total Pre-Tax Income 		-3.59 -5.79 -1.72 -1.69 -2.04 -2.40 -1.78 -1.54 -1.14 -5.98 -1.15
Total Operating Income		 -3.16 -3.06 -1.77 -1.73 -2.08 -2.44 -1.81 -1.55 -1.32 -5.82 -1.10
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Operating Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 3.16 3.06 1.77 1.73 2.08 2.44 1.81 1.55 1.32 5.82 1.10
Selling, General & Admin Expense		 2.14 2.67 1.01 1.12 1.01 1.58 1.49 1.05 0.90 5.33 0.58
Research & Development Expense		 1.02 0.39 0.76 0.61 1.07 0.86 0.31 0.50 0.41 0.50 0.52
Total Other Income / (Expense), net		 -0.43 -2.73 0.05 0.04 0.04 0.04 0.02 0.01 0.18 -0.16 -0.05
Interest Expense		 0.43 2.73 -0.05 - -0.04 - -0.02 - -0.02 - -0.04
Other Income / (Expense), net		 - - - 0.00 0.00 - 0.00 -0.00 0.16 - -0.09
Basic Earnings per Share		 ($0.26) ($0.39) ($0.15) ($0.11) ($0.14) ($0.11) ($0.11) ($0.09) ($1.18) $0.03 ($0.03)
Weighted Average Basic Shares Outstanding		 13.64M 13.92M 14.78M 14.78M 15.07M 15.44M 16.65M 16.99M 19.27M 23.69M 41.94M
Diluted Earnings per Share		 ($0.26) ($0.39) ($0.15) ($0.11) ($0.14) ($0.11) ($0.11) ($0.09) ($1.18) $0.03 ($0.03)
Weighted Average Diluted Shares Outstanding		 13.64M 13.92M 14.78M 14.78M 15.07M 16.81M 16.92M 16.99M 19.27M 42.02M 42.02M
Weighted Average Basic & Diluted Shares Outstanding		 - 14.78M - 14.78M 16.56M 16.81M 16.92M 19.07M 41.88M 42.02M 42.02M

Annual Cash Flow Statements for MIRA Pharmaceuticals

This table details how cash moves in and out of MIRA Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -2.46 4.25 -1.77 3.51
Net Cash From Operating Activities		 -5.60 -4.53 -5.56 -4.66
Net Cash From Continuing Operating Activities		 -5.60 -4.53 -5.56 -4.66
Net Income / (Loss) Continuing Operations		 -7.06 -12 -7.85 -10
Consolidated Net Income / (Loss)		 -7.06 -12 -7.85 -10
Non-Cash Adjustments To Reconcile Net Income		 1.30 8.10 1.92 6.35
Changes in Operating Assets and Liabilities, net		 0.15 -0.65 0.37 -0.57
Net Cash From Investing Activities		 0.00 0.00 0.00 0.00
Net Cash From Continuing Investing Activities		 0.00 0.00 0.00 0.00
Net Cash From Financing Activities		 3.15 8.78 3.79 8.18
Net Cash From Continuing Financing Activities		 3.15 8.78 3.79 8.18
Issuance of Debt		 0.00 2.15 - 0.57
Issuance of Common Equity		 2.90 7.70 3.64 7.01
Other Financing Activities, net		 0.40 0.07 0.15 0.60
Cash Interest Paid		 0.00 0.00 0.00 0.00
Cash Income Taxes Paid		 - 0.00 0.00 0.00

Quarterly Cash Flow Statements for MIRA Pharmaceuticals

This table details how cash moves in and out of MIRA Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 5.84 -1.27 -1.07 -0.70 1.32 -1.31 -1.63 -0.48 1.91 3.71 -1.53
Net Cash From Operating Activities		 -1.76 -1.04 -1.05 -0.86 -1.84 -1.81 -1.63 -0.80 -1.10 -1.14 -1.20
Net Cash From Continuing Operating Activities		 -1.76 -1.04 -1.05 -0.86 -1.84 -1.81 -1.63 -0.80 -1.10 -1.14 -1.20
Net Income / (Loss) Continuing Operations		 -3.59 -5.79 -1.72 -1.69 -2.04 -2.40 -1.78 -1.54 -1.14 -5.98 -1.15
Consolidated Net Income / (Loss)		 -3.59 -5.79 -1.72 -1.69 -2.04 -2.40 -1.78 -1.54 -1.14 -5.98 -1.15
Non-Cash Adjustments To Reconcile Net Income		 1.43 5.78 0.50 0.60 0.27 0.55 0.87 0.49 0.21 4.77 0.20
Changes in Operating Assets and Liabilities, net		 -0.04 -0.29 0.17 0.22 -0.07 0.05 -0.72 0.25 -0.17 0.08 -0.25
Net Cash From Investing Activities		 - - 0.00 - - - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 - - 0.00 - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 7.60 -0.23 -0.02 0.16 3.16 0.49 0.00 0.32 3.01 4.84 -0.33
Net Cash From Continuing Financing Activities		 7.60 -0.23 -0.02 0.16 3.16 0.49 0.00 0.32 3.01 4.84 -0.33
Repayment of Debt		 - -1.01 - - - 0.01 0.00 - - - -0.33
Issuance of Common Equity		 - - 0.00 - 3.16 0.48 0.00 0.35 2.82 3.84 0.00

Annual Balance Sheets for MIRA Pharmaceuticals

This table presents MIRA Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.86 4.93 2.92 11
Total Current Assets		 0.49 4.86 2.89 11
Cash & Equivalents		 0.35 4.60 2.83 6.35
Short-Term Investments		 - - 0.00 4.68
Accounts Receivable		 0.00 0.01 - 0.04
Prepaid Expenses		 0.00 0.24 0.05 0.03
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.36 0.07 0.04 0.00
Total Liabilities & Shareholders' Equity		 0.86 4.93 2.92 11
Total Liabilities		 1.45 0.56 0.72 0.70
Total Current Liabilities		 1.37 0.56 0.72 0.70
Accounts Payable		 0.93 0.54 0.72 0.13
Accrued Expenses		 - - - 0.24
Other Current Liabilities		 0.27 0.01 0.00 0.33
Total Noncurrent Liabilities		 0.08 0.00 0.00 0.00
Commitments & Contingencies		 - - 0.00 0.00
Total Equity & Noncontrolling Interests		 -0.60 4.37 2.20 10
Total Preferred & Common Equity		 -0.60 4.37 2.20 10
Preferred Stock		 0.00 0.00 0.00 0.00
Total Common Equity		 -0.60 4.37 2.20 10
Common Stock		 8.71 26 31 50
Retained Earnings		 -9.30 -21 -29 -40

Quarterly Balance Sheets for MIRA Pharmaceuticals

This table presents MIRA Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 3.81 3.02 4.27 1.40 0.87 7.63 9.46
Total Current Assets		 3.71 2.93 4.23 1.36 0.83 7.60 9.43
Cash & Equivalents		 3.53 2.82 4.14 1.21 0.73 2.64 4.82
Short-Term Investments		 - - - - - 4.89 4.59
Accounts Receivable		 0.00 0.00 0.00 - - - 0.04
Prepaid Expenses		 0.19 0.11 0.09 0.16 0.10 0.06 0.02
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.09 0.08 0.04 0.04 0.04 0.04 0.00
Total Liabilities & Shareholders' Equity		 3.81 3.02 4.27 1.40 0.87 7.63 9.46
Total Liabilities		 0.65 0.80 0.69 0.11 0.30 0.08 0.11
Total Current Liabilities		 0.65 0.80 0.69 0.11 0.30 0.08 0.11
Accounts Payable		 0.64 0.78 0.69 0.10 0.30 0.08 0.03
Accrued Expenses		 - - - 0.01 0.00 0.00 0.08
Other Current Liabilities		 0.00 0.00 0.00 - - - 0.00
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 - - - - - - 0.00
Total Equity & Noncontrolling Interests		 3.16 2.22 3.57 1.29 0.57 7.55 9.35
Total Preferred & Common Equity		 3.16 2.22 3.57 1.29 0.57 7.55 9.35
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 3.16 2.22 3.57 1.29 0.57 7.55 9.35
Common Stock		 26 27 30 32 33 41 50
Retained Earnings		 -23 -25 -27 -31 -32 -34 -41

Annual Metrics And Ratios for MIRA Pharmaceuticals

This table displays calculated financial ratios and metrics derived from MIRA Pharmaceuticals' official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 14,780,885.00 41,876,087.00
DEI Adjusted Shares Outstanding		 0.00 0.00 14,780,885.00 41,876,087.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.53 -0.76
Growth Metrics		 - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -20.97% 5.95% -31.47%
EBIT Growth		 0.00% -20.97% 5.95% -31.47%
NOPAT Growth		 0.00% -20.97% 5.95% -30.86%
Net Income Growth		 0.00% -69.77% 34.46% -32.98%
EPS Growth		 0.00% -112.50% 40.00% -164.71%
Operating Cash Flow Growth		 0.00% 19.13% -22.69% 16.17%
Free Cash Flow Firm Growth		 0.00% 0.00% 20.51% -41.33%
Invested Capital Growth		 0.00% 72.57% -196.23% -0.84%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 7.16% -48.34%
EBIT Q/Q Growth		 0.00% 0.00% 7.16% -48.34%
NOPAT Q/Q Growth		 0.00% 0.00% 7.16% -47.66%
Net Income Q/Q Growth		 0.00% 0.00% 30.14% -52.25%
EPS Q/Q Growth		 0.00% 0.00% 35.44% 9.40%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -16.07% 12.57%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -32.05%
Invested Capital Q/Q Growth		 0.00% 0.00% -10.92% -4,847.44%
Profitability Metrics		 - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.15% 140.54% 97.93% 99.06%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 1,183.80% -634.30% -238.90% -165.87%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 1,183.80% -634.30% -238.90% -165.87%
Return on Equity Simple (ROE_SIMPLE)		 1,183.80% -273.92% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.93 -5.97 -5.61 -7.35
NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1,161.45% -252.11% -60.36% -44.68%
Return On Investment Capital (ROIC_SIMPLE)		 - -136.44% -255.16% -70.68%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -7.05 -8.53 -8.02 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -7.05 -8.53 -8.02 -11
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 0.00 0.00 8.58 6.09
Price to Tangible Book Value (P/TBV)		 0.00 0.00 8.58 6.09
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 -0.22 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00
Financial Leverage		 0.31 -1.26 -1.13 -1.10
Leverage Ratio		 -1.44 1.53 1.19 1.11
Compound Leverage Factor		 -1.44 2.15 1.17 1.10
Debt to Total Capital		 -28.73% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 -28.73% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 128.73% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.02 0.00 0.00 0.00
Net Debt to EBITDA		 0.03 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.03 0.00 0.00 0.00
Net Debt to NOPAT		 0.04 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00
Altman Z-Score		 -39.83 0.00 -6.46 47.03
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - -
Current Ratio		 0.36 8.71 3.99 15.75
Quick Ratio		 0.26 8.27 3.92 15.76
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -6.53 -5.19 -7.34
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -1.89 0.00 0.00
Operating Cash Flow to Interest Expense		 -546.81 -1.31 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -546.81 -1.31 0.00 0.00
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - -
Invested Capital		 -0.78 -0.21 -0.63 -0.64
Invested Capital Turnover		 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.57 -0.42 -0.01
Enterprise Value (EV)		 8.71 0.00 16 52
Market Capitalization		 8.93 0.00 19 63
Book Value per Share		 ($0.03) $0.31 $0.13 $0.25
Tangible Book Value per Share		 ($0.03) $0.31 $0.13 $0.25
Total Capital		 -0.46 4.37 2.20 10
Total Debt		 0.13 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00
Net Debt		 -0.22 -4.60 -2.83 -11
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.09 -0.30 -0.67 -0.67
Debt-free Net Working Capital (DFNWC)		 -0.74 4.30 2.16 10
Net Working Capital (NWC)		 -0.88 4.30 2.16 10
Net Nonoperating Expense (NNE)		 2.12 6.01 2.24 3.10
Net Nonoperating Obligations (NNO)		 -0.18 -4.59 -2.83 -11
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.64) ($0.51) ($1.35)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 18.57M 15.44M 23.69M
Adjusted Diluted Earnings per Share		 $0.00 ($0.64) ($0.51) ($1.35)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 18.57M 15.44M 42.02M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 14.78M 16.81M 42.02M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.93 -5.97 -5.61 -7.35
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 -687.60 -2.47 0.00 0.00
NOPAT to Interest Expense		 -481.32 -1.73 0.00 0.00
EBIT Less CapEx to Interest Expense		 -687.60 -2.47 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -481.32 -1.73 0.00 0.00
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for MIRA Pharmaceuticals

This table displays calculated financial ratios and metrics derived from MIRA Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 0.00 0.00 14,780,885.00 14,780,885.00 29,561,770.00 14,780,885.00 16,813,654.00 16,919,623.00 19,069,315.00 41,876,087.00 42,022,087.00
DEI Adjusted Shares Outstanding		 0.00 0.00 14,780,885.00 14,780,885.00 29,561,770.00 14,780,885.00 16,813,654.00 16,919,623.00 19,069,315.00 41,876,087.00 42,022,087.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.12 -0.11 -0.07 -0.16 -0.11 -0.09 -1.19 -0.14 -0.03
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% 0.00% -32.01% -78.38% 23.49% 20.24% -2.09% 10.66% 44.59% -138.94% 33.80%
EBIT Growth		 0.00% 0.00% -32.01% -78.38% 34.13% 20.24% -2.09% 10.66% 44.59% -138.94% 33.80%
NOPAT Growth		 0.00% 0.00% -32.01% -78.38% 34.13% 20.24% -2.09% 10.67% 36.73% -138.94% 38.87%
Net Income Growth		 0.00% 0.00% -28.09% -33.58% 43.03% 58.54% -3.84% 9.08% 44.34% -149.34% 35.52%
EPS Growth		 0.00% 0.00% -50.00% -10.00% 46.15% 71.79% 26.67% 18.18% -742.86% 127.27% 72.73%
Operating Cash Flow Growth		 0.00% 0.00% 2.40% -30.74% -4.59% -74.40% -55.31% 7.44% 40.45% 37.12% 26.30%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -94.14% -143.41% -69.94% -216.39% 63.31%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -196.23% 124.59% 72.79% 102.36% -0.84% -165.51%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -180.42% -12.34% 42.15% 2.12% -20.27% -17.11% 25.95% 14.35% 25.41% -405.03% 79.48%
EBIT Q/Q Growth		 -225.71% 3.28% 42.15% 2.12% -20.27% -17.11% 25.95% 14.35% 25.41% -405.03% 79.48%
NOPAT Q/Q Growth		 -225.71% 3.28% 42.15% 2.12% -20.27% -17.11% 25.95% 14.35% 14.82% -342.29% 81.06%
Net Income Q/Q Growth		 -183.37% -61.31% 70.32% 1.54% -20.84% -17.41% 25.67% 13.79% 26.02% -425.93% 80.78%
EPS Q/Q Growth		 -160.00% -50.00% 61.54% 26.67% -27.27% 21.43% 0.00% 18.18% -1,211.11% 102.54% -200.00%
Operating Cash Flow Q/Q Growth		 -166.53% 41.23% -1.40% 17.68% -113.22% 2.01% 9.70% 50.94% -37.18% -3.47% -5.84%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 29.44% -42.69% -45.21% -32.78% 11.53% 0.39% -170.36% 84.60%
Invested Capital Q/Q Growth		 0.00% 0.00% -67.22% -65.16% 3.31% -10.92% 113.88% -282.77% 108.37% -4,847.44% 90.98%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 113.54% 189.36% 97.15% 97.72% 98.19% 98.44% 98.81% 99.45% 98.64% 102.72% 96.24%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -634.30% -391.51% -1,152.27% -629.05% -238.90% -355.82% -556.87% -123.33% -165.87% -184.32%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6,923.14% 0.00% -41,330.44% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -634.30% -391.51% -1,152.27% -629.05% -238.90% -355.82% -556.87% -123.33% -165.87% -184.32%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -391.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.21 -2.14 -1.24 -1.21 -1.46 -1.71 -1.26 -1.08 -0.92 -4.08 -0.77
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -79.51% -27.32% -34.16% -28.31% -18.68% -22.04% -25.73% -3.69% -27.50% -7.12%
Return On Investment Capital (ROIC_SIMPLE)		 - -48.91% -39.21% -54.60% -40.77% -77.58% -97.64% -189.92% -12.21% -39.24% -8.26%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -3.16 -3.06 -1.77 -1.73 -2.08 -2.44 -1.81 -1.55 -1.15 -5.82 -1.20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.72 -3.06 -1.77 -1.73 -2.08 -2.44 -1.81 -1.55 -1.15 -5.82 -1.20
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 4.24 5.38 8.58 12.73 35.93 3.44 6.09 4.81
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 4.24 5.38 8.58 12.73 35.93 3.44 6.09 4.81
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 173.77 0.00 1,368.01 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.05 -1.11 -1.27 -1.16 -1.13 -1.06 -1.27 -1.05 -1.10 -1.00
Leverage Ratio		 0.00 1.53 1.21 1.36 1.19 1.19 1.17 1.39 1.07 1.11 1.02
Compound Leverage Factor		 0.00 2.90 1.17 1.33 1.17 1.18 1.16 1.39 1.06 1.14 0.98
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 -5.42 7.25 -0.16 59.03 -16.32 179.93 48.43 229.82
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 8.71 5.70 3.68 6.11 3.99 12.86 2.79 90.53 15.75 82.16
Quick Ratio		 0.00 8.27 5.41 3.54 5.98 3.92 11.36 2.45 89.79 15.76 82.28
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 -0.88 -0.62 -0.89 -1.29 -1.71 -1.51 -1.51 -4.07 -0.63
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -4.12 -0.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -4.12 -0.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 -0.21 -0.36 -0.59 -0.57 -0.63 0.09 -0.16 0.01 -0.64 -0.06
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.00 -0.36 -0.59 -0.57 -0.42 0.45 0.43 0.58 -0.01 -0.15
Enterprise Value (EV)		 0.00 0.00 0.00 6.59 15 16 15 20 18 52 36
Market Capitalization		 0.00 0.00 0.00 9.42 19 19 16 20 26 63 45
Book Value per Share		 $0.00 $0.31 $0.21 $0.15 $0.24 $0.13 $0.08 $0.03 $0.40 $0.25 $0.22
Tangible Book Value per Share		 $0.00 $0.31 $0.21 $0.15 $0.24 $0.13 $0.08 $0.03 $0.40 $0.25 $0.22
Total Capital		 0.00 4.37 3.16 2.22 3.57 2.20 1.29 0.57 7.55 10 9.35
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -4.60 -3.53 -2.82 -4.14 -2.83 -1.21 -0.73 -7.54 -11 -9.41
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -0.30 -0.47 -0.69 -0.61 -0.67 0.05 -0.20 -0.02 -0.67 -0.09
Debt-free Net Working Capital (DFNWC)		 0.00 4.30 3.06 2.14 3.54 2.16 1.26 0.53 7.51 10 9.31
Net Working Capital (NWC)		 0.00 4.30 3.06 2.14 3.54 2.16 1.26 0.53 7.51 10 9.31
Net Nonoperating Expense (NNE)		 1.38 3.65 0.48 0.48 0.59 0.69 0.52 0.46 0.22 1.91 0.38
Net Nonoperating Obligations (NNO)		 0.00 -4.59 -3.51 -2.81 -4.14 -2.83 -1.21 -0.73 -7.54 -11 -9.41
Total Depreciation and Amortization (D&A)		 0.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.39) ($0.12) $0.00 ($0.14) ($0.11) ($0.11) ($0.09) ($1.18) $0.03 ($0.03)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 13.92M 19.71M 0.00 15.07M 15.44M 16.65M 16.99M 19.27M 23.69M 41.94M
Adjusted Diluted Earnings per Share		 $0.00 ($0.39) ($0.12) $0.00 ($0.14) ($0.11) ($0.11) ($0.09) ($1.18) $0.03 ($0.03)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 13.92M 19.71M 0.00 15.07M 16.81M 16.65M 16.99M 19.27M 42.02M 42.02M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 14.78M 0.00 0.00 16.56M 16.81M 16.92M 19.07M 41.88M 42.02M 42.02M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.21 -2.14 -1.24 -1.21 -1.46 -1.71 -1.26 -1.08 -0.92 -4.08 -0.77
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -7.39 -1.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -5.17 -0.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -7.39 -1.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -5.17 -0.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

MIRA Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, MIRA Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

MIRA Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$10.44 million in 2025, rising from -$7.06 million in 2022. The previous period was -$7.85 million in 2024. See MIRA Pharmaceuticals' forecast for analyst expectations on what's next for the company.

MIRA Pharmaceuticals' total operating income in 2025 was -$10.49 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $10.49 million

Over the last 3 years, MIRA Pharmaceuticals' total revenue changed from $0.00 in 2022 to $0.00 in 2025, a change of 0.0%.

MIRA Pharmaceuticals' total liabilities were at $702.07 thousand at the end of 2025, a 2.9% decrease from 2024, and a 51.7% decrease since 2022.

In the past 3 years, MIRA Pharmaceuticals' cash and equivalents has ranged from $350.98 thousand in 2022 to $6.35 million in 2025, and is currently $6.35 million as of their latest financial filing in 2025.

Over the last 3 years, MIRA Pharmaceuticals' book value per share changed from -0.03 in 2022 to 0.25 in 2025, a change of -831.9%.


Related Companies

Financial statements for NASDAQ:MIRA last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel